Nurix Therapeutics (NASDAQ:NRIX) Rating Increased to Sell at Wall Street Zen

Posted by Stanley Muller on Jul 12th, 2026

Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) was upgraded by research analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Sunday.

Other analysts have also issued research reports about the stock. Royal Bank Of Canada raised their price target on shares of Nurix Therapeutics from $30.00 to $33.00 and gave the company an “outperform” rating in a research report on Friday. Jefferies Financial Group increased their target price on shares of Nurix Therapeutics from $41.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, June 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Nurix Therapeutics in a research report on Tuesday, April 21st. Truist Financial lifted their price target on Nurix Therapeutics from $32.00 to $34.00 and gave the company a “buy” rating in a research note on Friday. Finally, Wells Fargo & Company lowered Nurix Therapeutics from an “overweight” rating to a “hold” rating and cut their price target for the company from $28.00 to $25.00 in a research note on Monday, June 8th. Twelve investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Nurix Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $33.77.

Check Out Our Latest Research Report on NRIX

Nurix Therapeutics Trading Down 6.6%

Nurix Therapeutics stock traded down $1.63 during mid-day trading on Friday, hitting $23.06. The company had a trading volume of 1,552,950 shares, compared to its average volume of 2,287,902. Nurix Therapeutics has a 12-month low of $8.19 and a 12-month high of $25.08. The company’s fifty day moving average is $18.44 and its 200-day moving average is $17.37. The company has a market capitalization of $2.38 billion, a price-to-earnings ratio of -6.68 and a beta of 1.80.

Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) last posted its earnings results on Thursday, July 9th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.08). Nurix Therapeutics had a negative net margin of 928.44% and a negative return on equity of 73.57%. The firm had revenue of $9.04 million for the quarter, compared to analysts’ expectations of $15.29 million. As a group, sell-side analysts expect that Nurix Therapeutics will post -2.88 EPS for the current fiscal year.

Insider Activity at Nurix Therapeutics

In other Nurix Therapeutics news, insider Gwenn Hansen sold 5,394 shares of Nurix Therapeutics stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $20.00, for a total transaction of $107,880.00. Following the sale, the insider owned 115,005 shares of the company’s stock, valued at $2,300,100. The trade was a 4.48% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Houte Hans Van sold 14,055 shares of Nurix Therapeutics stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $16.60, for a total transaction of $233,313.00. Following the sale, the chief financial officer directly owned 37,592 shares in the company, valued at approximately $624,027.20. This trade represents a 27.21% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 25,051 shares of company stock valued at $434,466 over the last quarter. 6.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Nurix Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of NRIX. General Atlantic L.P. purchased a new stake in Nurix Therapeutics in the 4th quarter valued at $92,899,000. Vanguard Group Inc. raised its holdings in shares of Nurix Therapeutics by 32.5% during the 4th quarter. Vanguard Group Inc. now owns 5,949,512 shares of the company’s stock worth $112,862,000 after acquiring an additional 1,460,736 shares during the period. Baker BROS. Advisors LP raised its holdings in shares of Nurix Therapeutics by 20.0% during the 4th quarter. Baker BROS. Advisors LP now owns 4,658,556 shares of the company’s stock worth $88,373,000 after acquiring an additional 776,431 shares during the period. Flax Pond Capital LLC acquired a new position in shares of Nurix Therapeutics during the 4th quarter valued at about $1,521,000. Finally, Perceptive Advisors LLC grew its holdings in shares of Nurix Therapeutics by 151.1% in the fourth quarter. Perceptive Advisors LLC now owns 3,555,877 shares of the company’s stock valued at $67,455,000 after purchasing an additional 2,139,728 shares during the period.

Key Headlines Impacting Nurix Therapeutics

Here are the key news stories impacting Nurix Therapeutics this week:

Positive Sentiment: Roche collaboration news was a major catalyst: Nurix said it entered a global partnership for bexobrutideg with potential total payments of up to $2.3 billion, including a $700 million upfront payment. Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Positive Sentiment: Royal Bank of Canada raised its price target on Nurix Therapeutics from $30 to $33 and reiterated an outperform rating, signaling confidence in upside from current levels.
Positive Sentiment: Stifel Nicolaus lifted its target from $34 to $40 and maintained a buy rating, while Needham and BTIG also reaffirmed buy ratings with targets of $34 and $32, respectively, adding to the bullish analyst tone.
Neutral Sentiment: Nurix reported second-quarter 2026 results with an EPS loss of $0.81 and revenue of $9.04 million, both below estimates, which kept focus on the company’s pipeline and partnership potential rather than near-term fundamentals. Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Negative Sentiment: The earnings miss may cap enthusiasm somewhat, as the company posted a wider loss than expected and revenue came in well below consensus. Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates

Nurix Therapeutics Company Profile

(Get Free Report)

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.